Oncomed Pharmaceuticals Inc (NASDAQ:OMED) Shifting Institutional Investors Sentiment

Sentiment for Oncomed Pharmaceuticals Inc (NASDAQ:OMED)

Oncomed Pharmaceuticals Inc (NASDAQ:OMED) institutional sentiment decreased to 0.52 in 2018 Q4. Its down -0.61, from 1.13 in 2018Q3. The ratio dropped, as 13 institutional investors increased and started new positions, while 25 trimmed and sold stock positions in Oncomed Pharmaceuticals Inc. The institutional investors in our partner’s database reported: 16.90 million shares, down from 17.31 million shares in 2018Q3. Also, the number of institutional investors holding Oncomed Pharmaceuticals Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 13 Reduced: 12 Increased: 7 New Position: 6.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $34.43 million. The companyÂ’s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

It closed at $0.89 lastly. It is down 66.23% since May 8, 2018 and is downtrending. It has underperformed by 70.60% the S&P500.

Harbourvest Partners Llc holds 0.67% of its portfolio in OncoMed Pharmaceuticals, Inc. for 1.90 million shares. Bvf Inc Il owns 4.04 million shares or 0.39% of their US portfolio. Moreover, Birchview Capital Lp has 0.12% invested in the company for 172,557 shares. The New York-based Perceptive Advisors Llc has invested 0.05% in the stock. Cannell Peter B & Co Inc, a New York-based fund reported 303,071 shares.

More notable recent OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) news were published by: Investorplace.com which released: “3 Biotech Stocks That Will Thrive Amid Market Instability – Investorplace.com” on April 19, 2018, also Globenewswire.com with their article: “Mereo BioPharma Group plc (“Mereo” or the “Company” or the “Group”) Merger Update: Acquisition of OncoMed Pharmaceuticals, Inc. (“OncoMed”) – Result of OncoMed Stockholder Meeting – GlobeNewswire” published on April 18, 2019, Seekingalpha.com published: “OncoMed Pharma down 8% after hours on Celgene withdrawal from rosmantuzumab – Seeking Alpha” on October 17, 2018. More interesting news about OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) were released by: Bizjournals.com and their article: “Peninsula biotech tumbles as cancer trial fails, Bayer nixes drug option – San Francisco Business Times” published on April 10, 2017 as well as Bioworld.com‘s news article titled: “Stem-Cell Cancer Deal: Oncomed Gets $177M Upfront from Celgene, Potential $3B – BioWorld Online” with publication date: December 03, 2013.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.